Diego Díaz García, Medical Oncologist, CEO and Founder of CánCare, shared a post on X:
“Neoadjuvant PD-1/PD-L1 blockade + chemo shows promising results in borderline resectable/unresectable stage III NSCLC (T4/N2-N3):
29% pCR
42% major path response
Best outcomes in PD-L1 ≥50% + high TMB
KRAS/STK11 and KRAS/KEAP1 linked to poor response”
Title: Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
Authors: Biagio Ricciuti, Francesca Fusco, Alissa Cooper, Edoardo Garbo, Federica Pecci, Mihaela Aldea, Xinan Wang, Maria Mayoral Penalva, Michelle Ginsberg, Lynette M. Sholl, Mizuki Nishino, Alessandro Di Federico, Narek Shaverdian, Matthew Bott, Valentina Santo, Erino Rendina, Rocco Trisolini, Sara Ramella, Filippo Gallina, Enrico Melis, Simonetta Buglioni, Gabriele Minuti, Lorenza Landi, Paula A. Ugalde Figueroa, Alice T. Shaw, Jamie Chaft, Mark M. Awad, Federico Cappuzzo
You can read the Full Article on JAMA Oncology
More posts featuring Diego Díaz García.
